BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today ...

The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635 (c) (4), and were granted as a material inducement to employment in ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on ...

The option was issued on January 3, 2025, and has an exercise price equivalent to the closing price of the Company's common stock on the date of grant. The option vests in equal proportions on a ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...

The options are subject to the terms and conditions of LENSAR's 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant. LENSAR is a commercial-stage medical ...

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental ...

Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, ...

Sensata Technologies Holding plc Announces Inducement Grant Under New York Stock Exchange Listed Company Manual Rule 303A.08 ...